Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform By Investing.com

Coeptis Therapeutics Holdings, Inc. (COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that it has completed the exclusive license of key assets from Deverra Therapeutics Inc. (“Deverra”) related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages. The transaction enables Coeptis to further build its pipeline by adding a patented, elegant, and scalable allogeneic immune cell manufacturing platform that aligns with its existing SNAP-CAR and GEAR technologies, increasing the potential for accelerated product development.

As a result of the transaction, Coeptis acquires exclusive rights to two Investigational New Drug (IND) applications and two assets in the Phase 1 clinical trial stage (NCT04901416, NCT04900454) investigating infusion of DVX201, an unmodified natural killer (NK) cell therapy generated from pooled donor CD34+ cells, in hematologic malignancies and viral infections. In addition, Coeptis augments its existing portfolio of cell therapy product candidates with a distinctly scalable allogeneic cellular immunotherapy platform that is being developed to generate and deliver off-the-shelf (no HLA matching), cost effective, on-demand cell therapies to a broad patient population.

In addition to the Phase 1 assets, this transaction equips Coeptis to begin infusing its existing pipeline assets with allogeneic technologies that are clinical stage-ready, helping to accelerate development efforts on targeted novel products, including potentially the development of allogeneic engineered NK and MAC cell therapies.

“Finalizing this transaction represents a pivotal transition of Coeptis into a clinical stage company with novel, synergistic and differentiated cell therapy pipeline candidates,” said Dave Mehalick, President and CEO of Coeptis Therapeutics. “As we move forward, I am excited to work with Colleen Delaney, MD, a visionary scientist whose career has been dedicated to researching and advancing all aspects of cell therapy product development. A true leader in the field, Colleen’s experience and leadership will be invaluable as we progress our expanded pipeline towards our ultimate goal of bringing improved treatments to patients in need.”

Under the transaction, Coeptis paid to Deverra approximately $570,000 in cash and issued to Deverra 4,000,000 shares of Coeptis’ common stock.